RPS6KB1 and neoplasm: In particular, the combination enhances inhibition of both Fibroblast Growth Factor (FGF)- and VEGF-induced tumor angiogenesis against endothelial cells, acting on cell proliferation as well as tube formation; moreover, the combination strongly reduces mTOR-S6K-S6 signaling in tumor cells, as compared to monotherapy (Table 2) [80].